Circassia Appoints Sir Richard Sykes as Chairman of the Board


Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced the appointment of Sir Richard Sykes as Chairman of the Board. Sir Richard succeeds Charles Swingland who held the post of Executive Chairman following the establishment of the business earlier this year. Mr Swingland will remain with Circassia as Deputy Chairman and General Counsel.

Sir Richard brings to Circassia thirty years of pharmaceutical industry experience, having led Glaxo and subsequently Glaxo Wellcome as Chairman and Chief Executive, and GlaxoSmithKline as Chairman until 2002. He is currently Rector of Imperial College London and is a Fellow of Imperial College School of Medicine, a Fellow of King's College London and a Fleming Fellow at Lincoln College Oxford. He is also a Fellow of the Royal Society and Academy of Medical Sciences.

Sir Richard is currently Chairman of the UK Stem Cell Foundation and Chairs CATALYST, London's Council for the Advancement of Science and Industry. He is a Board member of the Higher Education Funding Council for England and Chair of the WHO International Advisory Board that oversees the International Clinical Trials Registry Platform.

Internationally, he is Chairman of the Singapore Biomedical Sciences International Advisory Council, Director of Bio*One Capital, the investment arm of the Singapore Economic Development Board, and a member of the International Advisory Panel of Temasek, which owns and manages the Singapore Government's direct investments. Sir Richard is also Senior Director of Rio Tinto Plc, Deputy Chairman of Lonza Group Ltd, Chairman of the Healthcare Advisory Group of APAX, Chairman of MerLion Pharmaceuticals Pte Ltd and a Non-Executive Director of Abraxis BioScience Inc.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances